BOSTON (AP) — BOSTON (AP) — Aktis Oncology Inc. (AKTS) on Thursday reported a loss of $24.1 million in its second quarter.
The Boston-based company said it had a loss of 44 cents per share.
The results met Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was also for a loss of 44 cents per share.
The clinical-stage oncology company posted revenue of $3.4 million in the period, which beat Street forecasts. Three analysts surveyed by Zacks expected $2.3 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AKTS at https://www.zacks.com/ap/AKTS
Copyright © 2026 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
